Adverse event reports following yellow fever vaccination
Nicole P. Lindsey(Vector (United States)), Edward B. Hayes(Centers for Disease Control and Prevention), Katherine Horan(Centers for Disease Control and Prevention), Betsy Schroeder(Centers for Disease Control and Prevention), Elizabeth D. Barnett, J. Erin Staples(Vector (United States)), Phyllis E. Kozarsky(Emory University), Barbara A. Slade(Office of the Director), Gary W. Brunette(Centers for Disease Control and Prevention), M. Miles Braun(Georgetown University), Alison F. Hinckley(Centers for Disease Control and Prevention), Elaine R. Miller(Office of the Director), Nina Marano(Centers for Disease Control and Prevention)
Cited by 278
Related Papers
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
|New England Journal of Medicine|2001|3.7k
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
|Arthritis & Rheumatism|2002|661
Management of Neonates Born at ≥35 0/7 Weeks’ Gestation With Suspected or Proven Early-Onset Bacterial Sepsis
|PEDIATRICS|2018|462
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
|Annals of Internal Medicine|2003|459
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
|Arthritis & Rheumatism|2002|448